PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24846338-13	2014	CONCLUSIONS AND IMPLICATIONS: Vortioxetine increased wakefulness and increased frontal cortical activity, most likely because of its 5-HT7 and 5-HT3 antagonism and 5-HT1A agonism.	Vortioxetine	30-42	5-hydroxytryptamine receptor 1A	Rattus norvegicus	164-170	
25665528-1	2015	RATIONALE: Vortioxetine is a novel multimodal antidepressant that is a 5-HT1B receptor partial agonist, a 5-HT1A receptor agonist, an inhibitor of the serotonin (5-HT) transporter, and a 5-HT1D, 5-HT3, and 5-HT7 receptor antagonist in vitro.	Vortioxetine	11-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112	
25665528-2	2015	In vivo studies have shown that vortioxetine enhances levels of 5-HT and desensitizes 5-HT1A autoreceptors.	Vortioxetine	32-44	5-hydroxytryptamine receptor 1A	Rattus norvegicus	86-92	
25665528-9	2015	Long-term administration of vortioxetine and escitalopram (both at 5 mg/kg/day) induced an increase of tonic activation of the 5-HT1A receptors in CA3 pyramidal neurons, resulting in an increase in 5-HT transmission.	Vortioxetine	28-40	5-hydroxytryptamine receptor 1A	Rattus norvegicus	127-133	
25665528-11	2015	CONCLUSIONS: Desensitization of 5-HT1B autoreceptor and an increase of tonic activation of 5-HT1A receptors in the hippocampus may contribute to the antidepressant effect of vortioxetine.	Vortioxetine	174-186	5-hydroxytryptamine receptor 1A	Rattus norvegicus	91-97	
24846338-2	2014	Vortioxetine is a 5-HT3 , 5-HT7 , and 5-HT1D receptor antagonist, 5-HT1B partial agonist, 5-HT1A agonist, and 5-HT transporter inhibitor.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	90-96	
23916504-0	2014	Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	142-148	
23916504-8	2014	Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) <=0.1mg/kg (~80% 5-HT3 receptor occupancy; OR) and <=3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ~15%, 60%, 95%) in SA.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	173-179	
23916504-12	2014	vortioxetine administration significantly improved memory performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors, respectively.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	130-136	
23916504-13	2014	Vortioxetine"s effects on SA performance may involve 5-HT1A receptor agonism, but not 5-HT3 receptor antagonism, whereas the effects on OR performance may involve 5-HT3 receptor antagonism and 5-HT1A receptor agonism.	Vortioxetine	0-12	5-hydroxytryptamine receptor 1A	Rattus norvegicus	53-59